Endoceutics Case Study – Impact of SOLABS QM10 on Daily Activities
About Endoceutics
Endoceutics is a private pharmaceutical company operating in the fields of women’s health and hormone-sensitive cancer prevention and treatment.
Context
Endoceutics uses SOLABS’ Essentials (Document Control) and the following add-ons: Training Records Management and Change Control.
In June 2020, I interviewed Lyne Lavoie, Endoceutics’ Director of Data Management and Document Control along with Olga Kwan-Lock, Quality Assurance Manager. The purpose of this interview was to discuss the impacts of SOLABS QM10 on Endoceutics’ daily activities.
Key Takeaways
In the midst of COVID 19, the benefits of QM10 have been instantaneous. It has allowed users to easily transition towards working from home as they have access to what they need through the software. Olga Kwan-Lock
What our end-user community enjoys most is being able to use the software from anywhere, at anytime. Olga Kwan-Lock
QM10 is a tool which assists with decision making, projects and regulatory submissions. This is important for a company’s growth and justifies continuous investment in the software. Olga Kwan-Lock
For a company with multiple facilities, using a software with remote capabilities like SOLABS’ QM10 is a must. Lyne Lavoie
QM10 allows for better visibility of documents, training and processes. Lyne Lavoie
Compared to a paper-based system QM10 saves the trouble of figuring out on whose desk a document is sitting. Lyne Lavoie
QM10 helps avoid confusion when approving documents, as the software always provides the latest versions. Lyne Lavoie
The ability to approve documents remotely is something we have enjoyed for a long time. For a company with multiple facilities like ours, the only viable option is to have an electronic system like QM10. Lyne Lavoie
Our managers enjoy receiving a weekly report by email that provides the status of trainings they are responsible for thanks to QM10’s reporting capability. Lyne Lavoie
Comments
0 comments
Please sign in to leave a comment.